https://www.selleckchem.com/pr....oducts/canagliflozin
and identified S100A6 as a possible biomarker and therapeutic target for PC and T2DM patients. This study firstly revealed that the regulation of endodermal cell fate specification may be common pathogenesis of PC and T2DM and identified S100A6 as a possible biomarker and therapeutic target for PC and T2DM patients. Exenatide has been demonstrated beneficial effects on patients with type 2 diabetes mellitus (T2DM) regarding lipid metabolism. However, the potential mechanism remains unclear. We used a lipidomic approach to evaluate
Like
Comment
Share
